



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Renato MONTEIRO et al.

Conf. No.: 2086

Appl. No.: 10/591,642

Examiner: Michael Edward SZPERKA

Filed: July 16, 2007

Art Unit: 1644

For: **Monovalent Ligand of the FcαR1 Receptor as an Anti-Inflammatory Agent**

RESPONSE TO RESTRICTION REQUIREMENT

Responsive to the Restriction Requirement of August 12, 2009, Applicants provisionally elect with traverse to prosecute claims 5-19 (Group I) with traverse. Further, Applicants provisionally elect the species allergy, and, in particular, asthma.

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claims 1-4 (Cancelled)

5. (Previously Presented) A method of treating an inflammatory disease in a mammal, which comprises administering to the mammal monovalent antibody fragments directed against Fcα1RI receptor.

6. (Previously Presented) The method of claim 5, wherein the monovalent antibody fragments are directed against EC2 domain of the Fcα1RI receptor.

7. (Previously presented) The method of claim 5, wherein the inflammatory disease is selected from the group consisting of lupus, rheumatoid arthritis, diabetes, nephritis interstitial renal fibrosis, obstructive nephropathy and gut inflammatory disorders.

8. (Previously Presented) The method of claim 5, wherein the inflammatory disease is an allergy.